Page 415 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C3.2. KQ3 multivariable analyses

Author Factors Data source Duration Analyzed Population WW/AS Methods Results as described in paper
yr sample characteristics definitions
PMI
Receipt of
AS/WW
versus
alternative
treatments
66
Harlan Clinical, CaPSURE 1989- 5365 Localized No active Logistic 1. low vs. high risk (D’Amico),
2003 social, 2000 prostate ca treatment regression OR=5.1 (CI 3.8, 6.9)
14532780 insurance predicts WW 2. >75 yr vs. <65 yr, OR=14.3 (CI
vs. active 9.1, 22.5)
treatment 3. comorbidity score >1 vs. 0-1,
OR=1.43 (CI 1.1, 1.8)
4. private ins. vs. Medicare,
OR=0.7 (CI 0.5, 1.0)

NS: academic vs. community;
black vs. white; education; income;
in relationship
Meng 179 Clinical, CaPSURE 1989- 6074 Localized Not Multinomial 1. ≥70 yr vs. <70 yr, OR=49.4 (CI
2005 insurance 2002 prostate ca – explicitly logistic 13.2, 185.4)
15821485 high risk provided regression 2. PSA >20 vs. ≤10, OR=4.6 (CI
WW vs. RP 1.7, 12.8)
3. Medicare + suppl vs. private,
OR=9.2 (CI 2.1, 39.2)

NS: Gleason, T stage,
comorbidities, marital status

C-125